Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability ...

Clinical data supporting mechanism of action reinforce potential as a novel cancer treatmentBRISBANE, Calif., March 25, 2025 ...

Abstract Highlights ORIC-944 is a potent, highly selective, orally bioavailable, allosteric inhibitor of PRC2 that demonstrates best-in-class drug properties, including potency, solubility, and ...

This presentation will highlight a preclinical dataset that provides insights into the role of inhibiting TGF-β in overcoming acquired KRAS-G12C-inhibitor drug-resistant KRAS-G12C-mutated lung cancer.

This abstract is a sub-study of the TIGeR-PaC clinical trial. The combination product candidate (IAG), which is enabled by the FDA-cleared RenovoCath device, is currently under investigation and ...

The findings of this model support KIO-104 as a promising therapeutic candidate for both the prevention and treatment of PVR.

Jessica Adsit, MS, CGC is the 2025 recipient of the. The ACMG Foundation for Genetic and Genomic Medicine presented Ms. Adsit this award for her platform presentation, “Next Generation Sequencing in ...

Data evaluating safety and early signals of efficacy including updated local PFS from the completed dose escalation part of a Phase 1 study of re-irradiation with JNJ-1900 (NBTXR3) for patients ...

Louise Bourgeois, Eva Hesse, Alice Adams is the first exhibition to bring together sculpture by three pioneering artists of the 20th century ...

C.A. Details of the poster presentation are as follows: Abstract Title: ADI-270, an Armored Allogeneic Anti-CD70 γδ CAR T Cell Therapy, Demonstrates Improved Efficacy and Safety in Preclinical Models ...

Presentation Details ... 2025, 8:00 AM CT The abstract is now publicly accessible through the MDA website here. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage ...